Jeremy Andrew Squire - Toxicology

Author Information

Jeremy Andrew Squire is a prominent researcher affiliated with the Department of Genetics at the Medicine School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. His research focuses primarily on the genetic and molecular aspects of cancer, particularly prostate cancer. Over the years, he has made significant contributions to understanding the immune response and genetic mutations in cancer development and progression.

Research Contributions

Jeremy Andrew Squire has an extensive research portfolio that highlights his expertise in cancer genetics and molecular biology. In recent years, his work has focused on the expression levels of MHC class-I/-II in CDK12 mutated prostate cancer patients, genetic aspects of primary bone tumors, and the role of somatic mutations in the immune response within the tumor microenvironment of prostate cancer. Notably, his research has explored the link between PTEN loss and immune evasion in tumors, as well as the potential of artificial intelligence in assessing cancer biomarkers. His studies have paved the way for precision therapeutics and improved diagnostic applications in both solid and hematological tumors.

Aliases

Jeremy Andrew Squire is known by several aliases in academic publications, including:

J. Squire Jeremy Andrew Squire Jeremy Squire Jeremy A. Squire J Squire J. A. Squire Jeremy A Squire J A Squire J.a. Squire

Publication and Citation Metrics

Metric	Value
Citation Count	39,201
H-index	85
Paper Count	441

Publications:

Quantitative MHC class-I/-II expression levels in CDK12 mutated prostate cancer patients reveal intratumorally T cell adaptive immune response in tumors

DOI: 10.1101/2022.04.16.487364

Year: 2022

Genetic aspects of primary bone tumors

DOI: 10.1016/b978-0-12-821666-8.00059-1

Year: 2022

Abstract 1818: ZEB1 expression is associated with the PTEN loss and TMPRSS2 ERG fusion immune evasion phenotype in prostate cancer

DOI: 10.1158/1538-7445.AM2021-1818

Year: 2021

Epithelial–Mesenchymal Transition Signaling and Prostate Cancer Stem Cells: Emerging Biomarkers and Opportunities for Precision Therapeutics

DOI: 10.3390/genes12121900

Year: 2021

The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer

DOI: 10.3390/ijms22179550

Year: 2021

Multitarget fluorescence in situ hybridization diagnostic applications in solid and hematological tumors

DOI: 10.1080/14737159.2021.1887733

Year: 2021

High throughput assessment of biomarkers in tissue microarrays using artificial intelligence: PTEN loss as a proof-of-principle in multi-center prostate cancer cohorts

DOI: 10.1038/s41379-020-00674-w

Year: 2020

Emerging role of PTEN loss in evasion of the immune response to tumours

DOI: 10.1038/s41416-020-0834-6

Year: 2020

Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN).

DOI: 10.1093/jnci/djaa032

Year: 2020

The Dual Role of Serotonin in Colorectal Cancer

DOI: 10.1016/j.tem.2020.04.008

Year: 2020